Allogene Therapeutics, Inc. Letters of Credit Outstanding, Amount
Allogene Therapeutics, Inc. (ALLO) had Letters of Credit Outstanding, Amount of $6.00 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes
us-gaap:LettersOfCreditOutstandingAmount · last filed 2026-08-12
- 2026-06-30: Letters of Credit Outstanding, Amount $6.00M.
- 2026-03-31: Letters of Credit Outstanding, Amount $6.00M.
- 2025-12-31: Letters of Credit Outstanding, Amount $6.00M.
- 2025-09-30: Letters of Credit Outstanding, Amount $6.00M.
| Period end | Letters of Credit Outstanding, Amount | Letters of Credit Outstanding, Amount as first filed |
|---|---|---|
| 2026-06-30 | $6.00M 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $6.00M 10-Q · filed 2026-05-13 | |
| 2025-12-31 | $6.00M 10-Q · filed 2026-08-12 | |
| 2025-09-30 | $6.00M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $6.00M 10-Q · filed 2025-08-13 | |
| 2025-03-31 | $6.00M 10-Q · filed 2025-05-13 | |
| 2024-12-31 | $6.00M 10-K · filed 2026-03-12 | |
| 2024-09-30 | $6.00M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $6.00M 10-Q · filed 2024-08-07 | |
| 2024-03-31 | $6.00M 10-Q · filed 2024-05-13 | |
| 2023-12-31 | $6.00M 10-K · filed 2025-03-13 | |
| 2023-09-30 | $6.00M 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $6.00M 10-Q · filed 2023-08-02 | |
| 2023-03-31 | $6.00M 10-Q · filed 2023-05-03 | |
| 2022-12-31 | $6.00M 10-K/A · filed 2024-03-14 | |
| 2022-09-30 | $6.00M 10-Q · filed 2022-11-02 | |
| 2022-06-30 | $6.00M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $6.00M 10-Q · filed 2022-05-04 | |
| 2021-12-31 | $6.00M 10-K/A · filed 2024-03-14 | |
| 2021-09-30 | $5.20M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $5.20M 10-Q · filed 2021-08-04 | |
| 2021-03-31 | $5.20M 10-Q · filed 2021-05-05 | |
| 2020-12-31 | $5.20M 10-K · filed 2022-02-23 | |
| 2020-09-30 | $5.20M 10-Q · filed 2020-11-04 | |
| 2020-06-30 | $4.30M 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $4.30M 10-Q · filed 2020-05-06 | |
| 2019-12-31 | $4.30M 10-K · filed 2021-02-25 | |
| 2019-02-28 | $3.00M 10-Q · filed 2019-08-07 | |
| 2018-10-31 | $200.00K 10-Q · filed 2019-08-07 | |
| 2018-08-31 | $1.00M 10-Q · filed 2019-08-07 | $900.00K 10-Q · filed 2018-11-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |